



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2024 [Online ahead of print]

To cite this Article:

Carriera L, Caporuscio S, Fantò M, et al. **Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review.** *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.3079

 ©The Author(s), 2024
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review

Lorenzo Carriera,¹ Sara Caporuscio,² Marta Fantò,³ Alice D'Abramo,⁴
Genesio Puzio,⁴ Luca Triolo,⁴ Angelo Coppola^{4,5}

¹Faculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome; ²Internal Medicine Complex Operational Unit, Ospedale San Filippo Neri, Local Health Unit Roma 1, Rome; ³Casa di Cura Villa Benedetta, Villa Benedetta Group SRL, Rome; ⁴Pulmonology Complex Operational Unit, Ospedale San Filippo Neri, ASL Roma 1, Rome; ⁵Saint Camillus International University of Health Sciences, Rome, Italy

Correspondence: Lorenzo Carriera, Faculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168 Rome, Italy.

Tel.: 0630156062.

E-mail: lorenzo.carriera01@icatt.it

Contributions: LC, AC, conceptualization, methodology; LC, SC, MF, AC, writing-original draft preparation; LC, SC, MF, AD, GP, LT, writing - review and editing; AC, supervision. All authors have read and agreed to the published version of the manuscript.

Conflict of interest: the authors have no conflicts of interest to declare.

Ethics approval and consent to participate: not applicable. There was no human participation and no personal data were used.

Informed consent: not applicable.

Funding: this study was not supported by any sponsor or funder.

Availability of data and materials: all data analyzed during are included in the article.

Abstract

Biological drugs have revolutionized the management of severe asthma, and a tailored treatment approach made it possible to consider remission as an achievable treatment target. The incidence of autoimmune diseases is increasing in many parts of the world. Patients suffering from severe asthma, eligible or already treated with an asthma-approved biologic agent, may suffer from another immune-mediated inflammatory disease (IMID) that could require the simultaneous use of a second monoclonal antibody. The real-life studies available in the literature describing the concurrent administration of an asthma-approved biologic agent with another biologic for a different immune disease, obtained through a systematic search on online databases based on monoclonal antibodies, were collected and analyzed. 26 articles were included in this review according to the prespecified inclusion and exclusion criteria. All included papers were retrospective in nature. Study designs were case reports (n=18), case series (n=3), retrospective chart reviews (n=3), retrospective observational studies (n=1), and cohort studies (n=1). The study is intended to present, within the current literature, all the administered combinations of severe asthma-approved biologics with monoclonal antibodies for a different indication. Those were grouped according to the IMID for whom the second biologic agent, with a different mechanism of action, was prescribed. The combinations prescribed to the cohort of patients specifically treating uncontrolled severe asthma were deeper evaluated in the discussion section, since an analysis of these therapeutic combinations deriving from real-life experiences may be useful to optimize the management of patients with severe asthma, ultimately leading to improved patient care and outcomes. Prospective registries and future studies are required to assess the safety and efficacy of combination therapies for severe asthmatic patients who suffer from an IMID.

Key words: severe asthma, immune mediated inflammatory diseases, biologics, combination therapy.

Introduction

The introduction of biological therapies has brought a great improvement in the treatment of many severe or difficult-to-treat diseases across a wide range of medical specialties, in particular in respiratory, rheumatological, gastroenterological, and dermatological fields [1,2]. The role of biologic agents in severe asthma is critical, since they have revolutionized the management of the disease by significantly reducing exacerbations and the need for oral corticosteroids (OCS), improving lung function and quality of life [3]. Nowadays the role of biologics in the management of severe asthma has pushed the scientific community to move forwards the concept of disease control towards increasingly ambitious goals, such as disease modifiers interventions or even clinical remission [4,5]. The burden of autoimmune diseases is progressively rising worldwide, and is predicted to further increase in the coming decades [6], perhaps due to changes in exposures to environmental factors or behavioral changes, and also the COVID-19 pandemic has been recently linked to an increased risk of developing autoimmune diseases [7]. As a consequence, new drugs which target specific cytokines of the immunological pathways involved in the diseases are being studied and developed [8]. At the same time, in clinical practice we saw an expansion of the population of patients who are candidates for or undergoing biological therapy for severe asthma. This raised the possibility to identify patients eligible to biological therapies also for different indications, and these patients could undergo therapeutic schemes entailing the use of two biological drugs. The administration of a combination of two biologics has been recently described in severe asthma patients suffering from uncontrolled severe asthma with evidence of both allergic and eosinophilic phenotypes or severe asthma and type-2 comorbidities. However, no guideline recommends this strategy, due to insufficient data about efficacy and safety, and also in reason of the high costs [9]. Some preliminary data deriving from real-life studies are available in literature, describing the concurrent administration of an asthma approved biologic agent with another biologic for a different autoimmune disease. It can be hypothesized that these cases will become more frequent in the near future, not only for a greater incidence of these pathologies, but also for the improved detection and the possibility of better and targeted treatments. Real-world data reporting the concurrent treatment with two biologics for severe asthma or a T2 comorbidity and for a second autoimmune disease have not been systematically explored, and need to be described and examined to assess the efficacy and the potential long-term risks deriving from different combinations of biologic therapies across several diseases. The aim of this review is to collect and summarize the experiences regarding the combinations of asthma-approved biologics alongside another biologic agent to treat a different autoimmune disease. No general consideration about safety and effectiveness of such combinations is made, and evidence deriving from existing literature is analyzed with specific reporting of

indications, biologic drugs, efficacy and safety for each study. Cases that describe the combinations of asthma approved biologics administered for uncontrolled severe asthma and another biologic drug are presented and discussed.

Materials and Methods

A comprehensive review is a systematic, scientifically designed review of a defined literature base that employs the rigor of original research in an effort to limit outcome bias. A rigorous search of the literature was performed, to identify the literature that meets the inclusion criteria as defined for the review.

Search strategy

A systematic search was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify the current literature about combination of biological therapies with asthma approved biologics and other monoclonal antibodies (mAbs) for the treatment of another concomitant condition. The search was conducted on the online databases MEDLINE (PubMed), Scopus and Cochrane Library, from inception to April 2024, and was followed by manual literature searches in the reference lists of the included articles to identify additional articles about this topic. The research string was as follows: (Benralizumab OR Dupilumab OR Mepolizumab OR Omalizumab OR Reslizumab OR Tezepelumab) AND (Dual OR Combination OR Simultaneous OR Combining OR Combined OR Concomitant OR Add-on) AND (Abatacept OR Adalimumab OR Alemtuzumab OR Anakinra OR Anifrolumab OR Belimumab OR Bimekizumab OR Brodalumab OR Canakinumab OR Certolizumab OR Etanercept OR Golimumab OR Guselkumab OR Infliximab OR Ixekizumab OR Natalizumab OR Ocrelizumab OR Ofatumumab OR Risankizumab OR Rituximab OR Sarilumab OR Secukinumab OR Tildrakizumab OR Tocilizumab OR Ustekinumab OR Vedolizumab).

Study selection

We included clinical trials, observational studies, case series, case reports, letters, published in English, that met the following criteria: (1) cases of combination of benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab with a second biologic agent. 2) the second biologic agent was prescribed to treat a different IMID. Small molecules Tyrosine Kinase Inhibitors (TKIs) were not considered for inclusion. Included studies were not restricted to patient demographics, studies with both adult and pediatric patients have been considered, without any publication date restriction. Review articles, studies unavailable as full-texts, abstract-only papers, were classified as ineligible for inclusion. Studies describing

combinations of asthma biologics for the treatment of severe asthma uncontrolled with a biologic monotherapy or for the treatment of severe asthma and type 2 comorbidities were excluded, as well as studies reporting combinations with a mAb approved for the treatment of malignancies.

Data extraction

Data extraction was conducted by one author (L.C.) to be subsequently discussed and checked by a second author (A.C.). Extracted data included the following items: author/year, study design, population size, pathologies for which dual biologic therapy was administered, prescribed biologic agents, follow up, efficacy, safety.

Data synthesis

The data were extracted and qualitatively synthesized. Because of the limited number of reports and the restricted total number of patients, also in consideration of the design of the studies and the heterogeneous nature of outcome measures, a quantitative analysis was not conducted. In particular, the focus of the paper is on patients with severe asthma receiving a second biological agent for a concomitant condition. Other associations deriving from the existing literature, obtained through a systematic search based on mAbs, will be presented in the results section and in dedicated tables, even when asthma was not the indication; these data are to be considered separated and will not be further analyzed in the discussion.

Results

The initial literature search generated 475 potentially eligible articles from the aforementioned databases, plus 6 records identified additionally by manual search. A total of 68 duplicates were identified and removed. After excluding 387 articles, 26 articles were included in this review according to the prespecified inclusion and exclusion criteria. A flow chart showing the study selection is presented in Figure 1.

Study characteristics

All included papers were retrospective in nature. Study designs were case report (n=18), case series (n=3), retrospective chart reviews (n=3), retrospective observational study (n=1), cohort studies (n=1). Across all studies, the observation period ranged from 0.13 years to 4 years. A total of 87 patient were identified. Three patients, all belonging to the study by Gisondi et al [10], were excluded from the current analysis, since 2 patients received a combination of two asthma approved biologics (dupilumab and omalizumab) and 1 patient received dupilumab in combination with cetuximab for the treatment of colorectal cancer, which is beyond the

scope of this article. A detailed summary of study characteristics is presented in *Supplementary Tables 1-5*. Studies were grouped according to IMIDs indications. *Supplementary Table 1* for dermatological pathologies (psoriasis and hidradenitis suppurativa) [11-24], *Supplementary Table 2* for IBDs (inflammatory bowel diseases) [10,12,14,25-28], *Supplementary Table 3* for RA (rheumatoid arthritis) [10,14,26,29-31], *Supplementary Table 4* for AS (ankylosing spondylitis) [10,12,14]. Six patients received two or more mAbs, of which at least one was not prescribed for an autoimmune disease, while other 29 patients received two different biologics to treat one uncontrolled pathology, therefore data of these patients were separated and described in a different section, *Supplementary Table 5* [10,14,32-36]. Figure 2 shows the reasons and how many patients received an asthma approved biologic, and Figure 3 describes the number of patients suffering from each autoimmune disease that required the co-administration of a second biologic agent. In Figure 4, all the combinations of mAbs administered in the studies included in the review and the number of patients who received such combination are described in detail, grouped depending on asthma biologics.

Efficacy

The efficacy of the combination therapy was examined by the authors of the included studies through an independent evaluation of the outcomes for each pathology treated with a biologic agent. Responses were evaluated at various time points using several validated clinical scores, specific for each disease. In some studies, efficacy data were descriptive and/or in photographic form, and in others not possible to assess due to study design or data presentation.

Adverse events

Nineteen of the included studies reported no adverse events. In seven studies adverse events were described, in most cases of minor severity. They are all presented in the specific tables.

Discussion

Asthma inflammation develops as a result of a complex interaction between the innate and the adaptive immune system. The main pathogenic mechanisms are often described as T2-high and T2-low [37]. T2-high endotypes have an immune-inflammatory response driven by T helper type 2 (Th2) cells and type 2 innate lymphoid cells (ILC2) and mediated by type 2 cytokines, such as interleukin (IL)-4, IL-5, and IL-13, each with different roles in the inflammatory cascade. IL-4 drives IgE production and B-cell class switching, IL-13 causes mucus production, airway remodelling and bronchial hyperresponsiveness, and IL-5 is responsible for eosinophil differentiation, activation and survival [38]. T2-low asthma is either

driven by neutrophilic (dependent on a Th1/Th17-mediated immune response) or paucigranulocytic inflammation [39]. Asthma biologics target cytokines within the T2 inflammatory pathway. These drugs interfere with T2-inflammation in different ways: omalizumab targets IgE; mepolizumab and reslizumab target IL5; benralizumab targets the IL5 receptor; and dupilumab targets IL4 and IL13. Tezepelumab, recently approved, targets thymic stromal lymphopoietin (TSLP), an epithelial derived cytokine released in response to multiple triggers, preventing its interaction with the receptor and thus inhibiting multiple downstream inflammatory pathways, and at the moment it's the only mAb approved for patients with either high or low levels of T2 biomarkers [40]. Autoimmune diseases are characterized by dysregulation of the immune system with aberrant activation of the adaptive immune system cells. Biological agents available for the treatment of autoimmune diseases have targets that include cytokines and their receptors, or cell subsets with a view to altered trafficking, modulation of cellular activation state or cellular depletion [1]. The classes of biological disease modifying anti rheumatic drugs (bDMARDs) currently available for use in Psoriatic arthritis, RA and AS are anti TNF- α , interleukins inhibitors, T Cell Co-Stimulation Inhibitors and B cell depletion therapy. Psoriasis can be treated with anti TNF- α agents and interleukins inhibitors. Anti TNF- α , interleukins inhibitors and integrin blockers are the biologic agents available for the treatment of IBDs. In view of the foregoing, it is evident that monoclonal antibodies approved for severe asthma and for IMIDs have different therapeutic targets and distinct mechanisms of action. Figure 5 summarizes the major mechanisms of action of the mAbs approved for severe asthma and IMIDs that were included in the search string.

IMIDs have been recognized to share some similar pathogenic mechanisms; in particular the dysregulation and over-expression of the pro-inflammatory cytokine tumor necrosis factor (TNF) has been recognized to play a pivotal role in the pathophysiology of IMIDs [41,42]. In both CD and UC, TNF- α is secreted with other cytokines, such as IL-1, IL-6, and IL-17, by Th1 cells, causing the accumulation of immune cells in the gut [43,44]. TNF- α is considered the major inflammatory cytokine involved in the pathogenesis of RA, as it is secreted from Th1 cells and macrophages and activates synovial fibroblasts and recruits other inflammatory cells [45]. In the pathogenesis of psoriasis, TNF- α is secreted from stressed keratinocytes, and together with IFN- γ and IL-17 causes keratinocyte hyperproliferation and epidermal changes [46,47].

Patients with inflammatory bowel disease (IBD) have a significantly increased prevalence of respiratory symptoms, asthma, and chronic rhinosinusitis (CRS) than those without IBD [48]. Recent studies highlighted the association between asthma and rheumatoid arthritis (RA) [49,50]. Interestingly, lung inflammation is thought to be involved in the pathogenic

mechanisms leading to the development of RA, since inflammation of the mucosa of the respiratory system upregulates citrullination, that could trigger immunity and the production of anti-citrullinated protein antibodies (ACPAs) [51]. Therefore, the possible connections between asthma and T2 diseases and other inflammatory conditions are not fully explored, and understanding these potential links is important to increase knowledge of the underlying mechanisms of pathology. For example, TNF- α has been linked to a delay of eosinophil apoptosis via TNF-receptor 1, changing the longevity of these cells [52]. Eosinophils have been described to be involved in the development of inflammatory bowel disease (IBD), not only altering the structure and protective functions of the mucosal barrier and causing mucosal injury, but also playing an immunomodulatory role [53]. Interestingly, an increase in serum ECP values was observed in patients with RA compared with healthy subjects, and higher levels were associated with a more aggressive course [54]. Moreover, eosinophilia at diagnosis could affect the treatment response of RA patients [55].

Patients who have received omalizumab or dupilumab as asthma approved biologics represent the vast majority of the population included in the review. This is due to the fact that these medications are commonly used in dermatology to treat skin conditions uncontrolled with conventional therapies (CSU, AD, BP and PN). Since the role of Type 2 inflammation in skin conditions is well documented [56], the large use of these mAbs in clinical practice should not be surprising. Psoriasis was the most common IMID within the studies included in the review. It is noteworthy that biologics are approved for moderate to severe psoriasis, and it represents the pathology with the widest list of biologic agents available (TNF- α inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors), enabling treatment to be personalized according to patient-related factors and comorbidities [57]. These could have been some of the reasons for the high prevalence of psoriasis among patients treated with a combination of biologic therapies, as well as the high rate of comorbidities of psoriatic patients [58]. Although biologics for the treatment of Multiple Sclerosis (MS) were included in the search string, cases of combination with an asthma approved biologic agent have not been detected and are not available in literature to our knowledge. The cohort of patients receiving biologics for severe asthma is the focus of our dissertation. An analysis of these therapeutic combinations deriving from real life experiences may be of fundamental importance to optimize the management of patients with severe asthma, ultimately leading to improved patient care and outcomes, including quality of life. Mahar et al. [20] report the case of a woman treated for psoriasis and psoriatic arthritis with the IL-17 inhibitor secukinumab, who successfully received a second biologic agent for severe asthma and nasal polyps, with great improvement in asthma control. It is noteworthy that the previous discontinuation of each biological individually had caused a

relapse of the disease. The case series by Lommatzsch et al. [14] described 25 patients treated with several biologic combinations. Fifteen patients concomitantly received 2 biologics approved for severe asthma, and other 10 patients received one biologic for asthma plus another for the treatment of a concomitant but different disease. In this second group, which we are examining, the efficacy of the combination treatment was determined by evaluating the impact on asthma exacerbations, OCS use, asthma control (as measured with the asthma control test, ACT) and lung function (as measured with the forced expiratory volume in the first second, FEV₁, in % of the predicted value), before and during dual treatment. The study by Malik et al. [26] presents the cases of three patients with asthma and rheumatic diseases, who have benefited from different combined biologic therapies, providing data for each patient. Two patients, the former with CD and asthma and the latter with RA and asthma, obtained full control of both diseases. One patient affected by severe asthma and RA, despite improvement in both diseases, could not discontinue OCS, but reduced the dose to 11 mg/daily. The patient described by Yamada et al. [30], after the administration of a combination of biologics for severe asthma and AR, experienced a great improvement in respiratory function, quality of life, and did not require OCS courses. Both diseases were well controlled using the respective biologic agents, but relapsed following discontinuation, thus it was decided to administer the two mAbs simultaneously. Regarding side effects, a mild AE was described by Mahar et al. [20], with occasional sweating episodes and rhinorrhoea under the combination of dupilumab and secukinumab. Also, a mild GGT increase was observed in this patient, but was considered related to hepatic steatosis and not attributable to either secukinumab or dupilumab. No other relevant side effects were described in the other studies with asthmatic patients.

The analyzed existing data has some limitations, in particular related to the design of the studies (the majority of the literature consists of case reports and case series and no prospective studies or RCTs were found), to the small numbers of patients included and to the heterogeneous follow up duration. Moreover, a publication bias may be present, contributing to the uncertainty of the evaluation of the literature. Considering all these factors, it is not possible to provide any data or general consideration about the safety profile when biologics were combined.

Adherence to treatment is particularly important in severe asthma [59]. The consequences deriving from the necessity to receive two mAbs to treat two different pathologies could represent an additional factor to consider when designing the model of care of this group of patients. The psychological burden of this intervention, deriving also from administration related factors (i.e. the increased frequency of injections) has not been explored yet, and future studies of patient acceptability are needed to examine perceptions and perspectives of patients receiving a combination of biologics [60]. The costs might represent the main limitation to

combinations of biologic agents for severe asthma and IMIDs, in particular in middle and low income countries. Finally, regular clinical and laboratory monitoring of these patients is recommended to early detect potential significant side effects, such as an increased risk of infection, other disorders of the immune system or malignancies. However, when treating these complex patients, these potential risks must be balanced carefully against the risks deriving from uncontrolled severe diseases and the consequences deriving from ongoing therapies (as in the case of systemic side effects due to long term OCS therapy for severe asthma). Moreover, the difference of therapeutic targets and the distinct mechanisms of action of biologics approved for severe asthma and for IMIDs should be kept in mind, since this consideration could provide reassurance to clinicians regarding the risk of side effects and infections when comorbid patients require the simultaneous administration of two mAbs for uncontrolled diseases.

The production of new real life data would be valuable, and in this sense international registries could play a crucial role, enabling researchers and healthcare professionals to analyze disease trends, treatment strategies and outcomes, including safety profile.

Conclusions

The introduction of biologic therapies enabled a paradigm shift toward an era of precision medicine [61]. Previously, asthma treatment aimed for disease control rather than remission. However, the development of new biologic therapies allowed clinicians to set new ambitious goals, such as the possibility to achieve and maintain asthma remission [62]. It is very likely that cases of severe asthmatic patients candidates or undergoing biological therapy and requiring a second biologic agent for a different indication will be more frequent in the near future. Clinicians should be sensitized and prepared to manage patients with asthma and a concomitant IMID, in order to aim to achieve clinical remission for both diseases. Further studies on a larger number of patients are required to assess the safety and efficacy of combination therapies for severe asthmatic patients who suffer from an immune mediated inflammatory disease. Web-based observatory registries collecting demographic, clinical, functional and inflammatory data, treatments (including biologics) and comorbidities of these patients could be valuable to demonstrate whether the outcomes and the safety profile observed so far in real-world studies are replicable.

References

1. McInnes IB, Gravallesse EM. Immune-mediated inflammatory disease therapeutics: past, present and future. *Nat Rev Immunol* 2021;21:680-6.
2. Kuek A, Hazleman BL, Ostör AJK. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. *Postgrad Med J* 2007;83:251-60.
3. Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. *N Engl J Med* 2022;386:157-71.
4. Lugogo NL, Mohan A, Akuthota P, et al. Are we ready for asthma remission as a clinical outcome? *Chest* 2023;164:831-4.
5. Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? *Eur Respir J* 2022;60:2102583.
6. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment and prevention. *Curr Opin Immunol* 2023;80:102266.
7. Sharma C, Bayry J. High risk of autoimmune diseases after COVID-19. *Nat Rev Rheumatol* 2023;19:399-400.
8. Cao F, Liu YC, Ni QY, et al. Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019. *Autoimmun Rev* 2023;22:103359.
9. Carriera L, Fantò M, Martini A, et al. Combination of biological therapy in severe asthma: where we are? *J Pers Med* 2023;13:1594.
10. Gisondi P, Maurelli M, Costanzo A, et al. the combination of dupilumab with other monoclonal antibodies. *Dermatol Ther* 2022;13:7-12.
11. Koç Yıldırım S, Erbağcı E, Hapa A. Omalizumab treatment in combination with any other biologics: Is it really a safe duo? *Australas J Dermatol* 2023;64:229-33.
12. Fougousse AC, Becherel PA, Pallure V, et al. Combining omalizumab with another biotherapy. *Acta Derm Venereol* 2019;99:448-9.
13. Barry K, Zancanaro P, Casseres R, et al. A retrospective review of dupilumab and psoriasis biologic combination therapy. *J Dermatolog Treat* 2021;32:438-9.
14. Lommatzsch M, Suhling H, Korn S, et al. Safety of combining biologics in severe asthma: asthma-related and unrelated combinations. *Allergy* 2022;77:2839-43.
15. Gerger V, Rummenigge C, Pinter A, Kaufmann R. Safety and efficacy of blocking IL-4/13 and IL-23 in concomitant atopic dermatitis and psoriasis - two case reports. *J Dtsch Dermatol Ges* 2023;21:648-50.
16. Diluvio L, Vollono L, Zangrilli A, et al. Omalizumab and adalimumab: a winning couple. *Immunotherapy* 2020;12:1287-92.

17. Karstarli Bakay OS, Kacar N. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. *Dermatol Ther* 2022;35:e15638.
18. Kabbani M, Mboyo Mpita G, Benhadou F. Ustekinumab plus dupilumab in the treatment of concomitant psoriasis and prurigo nodularis. *J Eur Acad Dermatol Venereol* 2022;36:e1050-1.
19. Balestri R, Magnano M, Girardelli CR, et al. Long-term safety of combined biological therapy in a patient affected by arthropathic psoriasis and atopic dermatitis. *Dermatol Ther* 2020;33:e13498.
20. Mahar PD, Zubrinich CM, Manuelpillai N, Foley P. Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma. *Australas J Dermatol* 2021;62:506-8.
21. Diluvio L, Pensa C, Piccolo A, et al. Coexisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria. *Dermatol Ther* 2022;35:e15359.
22. Benko M, Hrvatin Stancic B, Lunder T. Two track biologic therapy for concurrent chronic spontaneous urticaria and psoriasis vulgaris in one patient. *Actas Dermosifiliogr* 2022;113:995-6.
23. Abdelmaksoud A, Temiz SA, Daye M, et al. Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: a case report and review of the literature. *J Cosmet Dermatol* 2023;22:1416-8.
24. Kaszycki MA, Pixley JN, Feldman SR. Concurrent atopic dermatitis and psoriasis successfully treated with dual biologic therapy. *Cutis* 2023;112:E13-6.
25. Spencer EA, Dolinger MT, Dubinsky MC. A single-center experience with dupilumab for atopic or psoriasiform dermatitis in patients with inflammatory bowel disease. *Dig Dis Sci* 2023;68:1121-4.
26. Malik M, Jones B, Williams E, et al. Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series. *Rheumatol Adv Pract* 2023;7:rkad018.
27. Alegre-Bailo A, Sánchez-Gilo A, Gonzalo González I, Vicente Martín FJ. Combination treatment with monoclonal antibodies: dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease. *Australas J Dermatol* 2024;65:63-6.
28. Patel B, Butterfield JH, Weiler CR, Kane SV. Tolerance and efficacy with simultaneous use of two monoclonal antibodies for a patient with hypereosinophilic syndrome and ulcerative colitis. *Monoclon Antib Immunodiagn Immunother* 2016;35:300-3.

29. Takeuchi N, Yamanishi A, Kumagai Y, Yokoyama T. Successful combined treatment with omalizumab and tocilizumab in a case of chronic spontaneous urticaria and rheumatoid arthritis: a case report and literature review. *Trends Immunother* 2022;6:1-3.
30. Yamada H, Hida N, Kurashima Y, et al. A case of severe eosinophilic asthma and refractory rheumatoid arthritis well controlled by combination of IL-5R α antibody and TNF α inhibitor. *Allergol Int* 2019;68:536-8.
31. Ghazanfar MN, Thomsen SF. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis. *J Dermatolog Treat* 2019;30:387-8.
32. Steinhoff M, Al-Marri F, Al Chalabi R, et al. Recalcitrant erythrodermic ichthyosis with atopic dermatitis successfully treated with dupilumab in combination with Guselkumab. *Skin Health Dis* 2022;2:e87.
33. Le ST, Herbert S, Haughton R, et al. Rituximab and omalizumab combination therapy for bullous pemphigoid. *JAMA Dermatol* 2024;160:107-9.
34. Kwon IJ, Kim T, Yoo DS, et al. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid. *J Dermatol* 2023;50:705-9.
35. Afiari A, Gabriel A, Gaiki MR. Concurrent use of mepolizumab and rituximab for eosinophilic granulomatosis with polyangiitis and multisystem involvement. *Cureus* 12:e9242.
36. Mutoh T, Shirai T, Sato H, et al. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review. *Rheumatol Int* 2022;42:2069-76.
37. Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. *Clin Rev Allergy Immunol* 2019;56:219-33.
38. Pelaia C, Crimi C, Vatrella A, et al. Molecular targets for biological therapies of severe asthma. *Front Immunol* 2020;11:603312.
39. Peri F, Amaddeo A, Badina L, et al. T2-low asthma: a discussed but still orphan disease. *Biomedicines* 2023;11:1226.
40. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med* 2021;384:1800-9.
41. Jang D in, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF- α) in autoimmune disease and current TNF- α inhibitors in therapeutics. *Int J Mol Sci* 2021;22:2719.

42. Doss GPC, Agoramoorthy G, Chakraborty C. TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases. *Front Biosci* 2014;19:1028-40.
43. Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn's disease. *Int J Mol Sci* 2018;19:2244.
44. Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. *J Clin Pharmacol* 2007;47:930-41.
45. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med* 2001;344:907-16.
46. Ogawa E, Sato Y, Minagawa A, Okuyama R. Pathogenesis of psoriasis and development of treatment. *J Dermatol* 2018;45:264-72.
47. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. *Int J Mol Sci* 2019;20:1475.
48. Kuenzig ME, Bishay K, Leigh R, et al. Co-occurrence of asthma and the inflammatory bowel diseases: a systematic review and meta-analysis. *Clin Transl Gastroenterol* 2018;9:188.
49. Kim JG, Kang J, Lee JH, Koo HK. Association of rheumatoid arthritis with bronchial asthma and asthma-related comorbidities: a population-based national surveillance study. *Front Med* 2023;10:1006290.
50. Shen TC, Lin CL, Wei CC, et al. The risk of asthma in rheumatoid arthritis: a population-based cohort study. *QJM* 2014;107:435-42.
51. Klareskog L, Catrina AI. Autoimmunity: lungs and citrullination. *Nat Rev Rheumatol* 2015;11:261-2.
52. Kankaanranta H, Ilmarinen P, Zhang X, et al. Tumour necrosis factor- α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF- κ B and AP-1. *PLoS One* 2014;9:e90298.
53. Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. *World J Gastroenterol* 2019;25:3503-26.
54. Hällgren R, Feltelius N, Svenson K, Venge P. Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein. *Clin Exp Immunol* 1985;59:539-46.
55. Guellec D, Milin M, Cornec D, et al. Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort. *RMD Open* 2015;1:e000070.
56. Belmesk L, Muntyanu A, Cantin E, et al. Prominent role of type 2 immunity in skin diseases: beyond atopic dermatitis. *J Cutan Med Surg* 2022;26:33-49.

57. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? *Am J Clin Dermatol* 2018;19:1-13.
58. Lotti T, Hercogova J, Prignano F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? *Dermatol Ther* 2010;23:119-22.
59. Bourdin A, Halimi L, Vachier I, et al. Adherence in severe asthma. *Clin Exp Allergy* 2012;42:1566-74.
60. Crimi C, Calabrese C, D'Amato M, et al. Patient and physician perspectives on biological treatment in severe asthma: a Severe Asthma Network Italy survey. *ERJ Open Res* 2023;9:00560-2023.
61. Menzies-Gow AN, Price DB. Clinical remission in severe asthma: how to move from theory to practice. *Chest* 2023;164:296-8.
62. Hansen S, Baastrup Søndergaard M, von Bülow A, et al. Clinical response and remission in patients with severe asthma treated with biologic therapies. *Chest* 2024;165:253-66.

Online supplementary material:

Supplementary Table 1. Combination of benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab with a second biologic agent to treat dermatological immune-mediated inflammatory disease.

Supplementary Table 2. Combination of benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab with a second biologic agent to treat inflammatory bowel diseases.

Supplementary Table 3. Combination of benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab with a second biologic agent to treat rheumatoid arthritis.

Supplementary Table 4. Combination of benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, tezepelumab with a second biologic agent to treat ankylosing spondylitis.

Supplementary Table 5. Other combinations of asthma-approved biologics with monoclonal antibodies of different nature with their respective indications, not suitable for inclusion in previous groups.




Figure 1. PRISMA 2020 Flowchart Diagram of the selected articles.

Indications	Number of Patients (n=87)
CSU	47
AD	24
Asthma	12
HES	1
Prurigo Nodularis	1
Systemic Mastocytosis	1
Bullous Pemphigoid	1

Figure 2. Indications for receiving an asthma approved biologic drug.

Indications	Number of Patients (n=87)
Psoriasis	56
Inflammatory Bowel Disease	18
Rheumatoid Arthritis	8
Ankylosing Spondylitis	3
Hidradenitis Suppurativa	2

Figure 3. IMID for whom a mAb in combination with an asthma approved biologic drug was administered.

Biologic agent combined with Omalizumab	Number of patients (n=50)	Biologic agent combined with Dupilumab	Number of patients (n=30)	Biologic agent combined with Mepolizumab	Number of patients (n=4)
SECUKINUMAB	n=20	GUSELKUMAB	n=8	RITUXIMAB	n=1
ADALIMUMAB	n=7	USTEKINUMAB	n=7	INFLIXIMAB	n=1
IXEKIZUMAB	n=7	SECUKINUMAB	n=3 ††	ETANERCEPT	n=1
ETANERCEPT	n=6	VEDOLIZUMAB	n=3	USTEKINUMAB	n=1
USTEKINUMAB	n=4	INFLIXIMAB	n=3		
INFLIXIMAB	n=3	TILDRAKIZUMAB	n=2 ‡	Biologic agent combined with Benralizumab	Number of patients (n=3)
TOCILIZUMAB	n=1	ABATACEPT	n=1	ETANERCEPT	n=2
TILDRAKIZUMAB	n=1	BRODALUMAB	n=1		
GUSELKUMAB	n=1 †	ETANERCEPT	n=1	GOLIMUMAB	n=1
		ADALIMUMAB	n=1		

Figure 4. Biologics administered concurrently with Omalizumab, Dupilumab, Mepolizumab and Benralizumab.

† The patient during Omalizumab treatment received different biologics, but we considered the last administered biologic. Table 1, Benko et al. (22)

†† The patient received firstly Benralizumab, later switched to Dupilumab. We considered the last administered biologic and included her under this list. Table 1, Mahar et al. (20).

‡ One patient received firstly Brodalumab, later switched to Tildrakizumab. We considered the last administered biologic and included her under this list. Table 1, Gerger et al. (15)

Biological Drugs	Mechanism of Action	Biological Drugs	Mechanism of Action
Benralizumab	Anti-IL-5 receptor alpha antibody; prevents the interaction between IL-5 and its receptor and promotes antibody-dependent cell-mediated cytotoxicity (ADCC) enhancing eosinophil apoptosis.	Etanercept	TNF receptor fusion protein; binds and neutralizes TNF-alpha.
Dupilumab	Anti-IL-4R α antibody; inhibits IL-4 and IL-13 signaling.	Golimumab	Anti-TNF-alpha antibody; inhibits TNF-alpha signaling
Mepolizumab	Anti-IL-5 antibody; binds to IL-5 and prevents IL-5 from binding to its receptor.	Guselkumab	Anti-IL-23p19 antibody; inhibits IL-23 signaling.
Omalizumab	Anti-IgE antibody; inhibits the binding of IgE to its receptor on mast cells and basophils.	Infliximab	Anti-TNF-alpha antibody; blocks TNF-alpha.
Reslizumab	Anti-IL-5 antibody; binds to IL-5 and prevents IL-5 from binding to its receptor.	Ixekizumab	Anti-IL-17A antibody; blocks IL-17A signaling.
Tezepelumab	Anti-TSLP (thymic stromal lymphopoietin) antibody; prevents interaction with TSLP receptor complex and inhibits TSLP signaling upstream in the inflammatory cascade.	Natalizumab	Anti- α 4 integrin antibody; inhibits leukocyte adhesion and migration across the blood-brain barrier.
Abatacept	CTLA-4-Ig fusion protein; inhibits T-cell activation by blocking CD80/CD86 on antigen-presenting cells.	Ocrelizumab	Anti-CD20 antibody; depletes B cells.
Adalimumab	Anti-TNF-alpha antibody; blocks TNF-alpha signaling.	Ofatumumab	Anti-CD20 antibody; depletes B cells.
Alemtuzumab	Anti-CD52 antibody; depletes T and B lymphocytes.	Risankizumab	Anti-IL-23p19 antibody; inhibits IL-23 signaling.
Anakinra	IL-1 receptor antagonist; blocks IL-1 signaling.	Rituximab	Anti-CD20 antibody; depletes B cells.
Anifrolumab	Anti-IFNAR1 (Type I interferon receptor) antibody; inhibits type I interferon signaling.	Sarilumab	Anti-IL-6 receptor antibody; blocks IL-6 signaling.
Belimumab	Anti-BAFF (B-cell activating factor) antibody; inhibits the survival of B cells.	Secukinumab	Anti-IL-17A antibody; blocks IL-17A signaling.
Bimekizumab	Anti-IL-17A and IL-17F antibody; blocks IL-17A and IL-17F signaling pathways.	Tildrakizumab	Anti-IL-23p19 antibody; inhibits IL-23 signaling.
Brodalumab	Anti-IL-17RA antibody; blocks the IL-17 receptor, inhibiting IL-17 signaling.	Tocilizumab	Anti-IL-6 receptor antibody; blocks IL-6 signaling.
Canakinumab	Anti-IL-1 β antibody; blocks IL-1 β signaling.	Ustekinumab	Anti-IL-12 and IL-23p40 antibody; inhibits IL-12 and IL-23 signaling.
Certolizumab	Anti-TNF-alpha antibody fragment (Fab); blocks TNF-alpha signaling.	Vedolizumab	Anti- α 4 β 7 integrin antibody; inhibits T-cell migration into the gut.

Figure 5. Mechanism of action of biological drugs included in the review.